SCHEMBL6177907

SCHEMBL6177907

CC(=O)SCC(C(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1)c1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A15 Q9H2J7 16/20 0.69
HRH1 P35367 6/20 0.68
FNTA P49354 5/20 0.68
FNTB P49356 5/20 0.68
PTAFR P25105 3/20 0.68
MEN1 O00255 1/20 0.63
NPC1 O15118 1/20 0.63
CACNA1F O60840 1/20 0.63
NR1I2 O75469 1/20 0.63
GMNN O75496 1/20 0.63
USP2 O75604 1/20 0.63
ABCB11 O95342 1/20 0.63
LMNA P02545 1/20 0.63
TP53 P04637 1/20 0.63
CHRM2 P08172 1/20 0.63
ABCB1 P08183 1/20 0.63
CYP3A4 P08684 1/20 0.63
ADORA3 P0DMS8 1/20 0.63
CYP2C8 P10632 1/20 0.63
CYP2D6 P10635 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6182089 0.88 SLC6A15 (0.73) SLC6A15HRH1FNTAFNTBPTAFR
SCHEMBL6179203 0.84 SLC6A15 (0.67) SLC6A15HRH1FNTAFNTBPTAFR
SCHEMBL8891276 0.83 SLC6A15 (0.83) SLC6A15HRH1FNTAFNTBPTAFR
Sch-37370 SCHEMBL29754039 0.82 PTAFR (1.00) SLC6A15HRH1FNTAFNTBPTAFR
Sch-37370 SCHEMBL29626524 0.82 PTAFR (1.00) SLC6A15HRH1FNTAFNTBPTAFR
Sch-37370 SCHEMBL3071641 0.82 PTAFR (1.00) SLC6A15HRH1FNTAFNTBPTAFR
SCHEMBL10570601 0.81 SLC6A15 (1.00) SLC6A15HRH1FNTAFNTBPTAFR
SCHEMBL8878015 0.81 SLC6A15 (0.86) SLC6A15HRH1FNTAFNTBPTAFR
SCHEMBL8878121 0.81 SLC6A15 (0.86) SLC6A15HRH1FNTAFNTBPTAFR
SCHEMBL3367280 0.81 SLC6A15 (0.82) SLC6A15HRH1FNTAFNTBPTAFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1123931-B1 Tricylic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases SCHERING CORP (US) 2005-06-01 EP disclosed
US-20020068742-A1 Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases BISHOP W ROBERT (US) 2002-06-06 US disclosed
US-6365588-B1 AS ANTINEOPLASTIC AGENT AND A POTENTIATING SCHERING CORPORATION 2002-04-02 US disclosed
EP-0723540-B1 TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES SCHERING CORP (US) 2001-12-12 EP disclosed
EP-1123931-A1 Tricylic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases SCHERING CORPORATION (US) 2001-08-16 EP disclosed
US-6242458-B1 INHIBITING FARNESYL PROTEIN TRANSFERASE IN A HUMAN SCHERING CORPORATION 2001-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068742-A1 Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases RASGRP1, CCNA1, CCNA2 SLC6A15 1804/4885HRH1 389/4885FNTA 516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.